SCHEMBL10150358

SCHEMBL10150358

CC(C)S(=O)(=O)N1CCN(c2nc(-c3ccccc3O)nc3c2CC[C@@H](C)C3)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
CYP1A2 P05177 1/20 0.40
CNR1 P21554 2/20 0.39
CNR2 P34972 2/20 0.39
ALDH1A1 P00352 4/20 0.38
MAPT P10636 4/20 0.38
KDM4E B2RXH2 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
ADORA1 P30542 1/20 0.38
SMAD3 P84022 1/20 0.38
TSHR P16473 3/20 0.37
LMNA P02545 1/20 0.37
F12 P00748 1/20 0.37
PIK3CD O00329 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10150356 0.89 MEN1 (0.42) GBA1MEN1KMT2ACYP2C9CYP2C19
SCHEMBL10150354 0.89 KMT2A (0.41) MEN1KMT2ACYP2C9CYP2C19NPSR1
SCHEMBL10150334 0.85 KDM4E (0.41) MEN1KMT2ACYP2C9CYP2C19NPSR1
SCHEMBL8299287 0.84 MEN1 (0.57) MEN1KMT2ANPSR1CYP1A2ALDH1A1
SCHEMBL8297570 0.84 SMAD3 (0.53) MEN1KMT2ANPSR1ALDH1A1MAPT
SCHEMBL10150299 0.84 ALDH1A1 (0.53) MEN1KMT2ANPSR1ALDH1A1MAPT
SCHEMBL8297579 0.84 ALDH1A1 (0.53) MEN1KMT2ANPSR1ALDH1A1MAPT
SCHEMBL10150306 0.84 SMAD3 (0.53) MEN1KMT2ANPSR1ALDH1A1MAPT
SCHEMBL8299612 0.83 ALDH1A1 (0.42) MEN1KMT2ANPSR1CNR1CNR2
SCHEMBL8299276 0.83 SMAD3 (0.52) MEN1KMT2ANPSR1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS KCNQ1, KCNN2, KCNH3 GBA1 439/4885MEN1 2441/4885KMT2A 3069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.